Compare PARP inhibitors (olaparib, niraparib, rucaparib) in ovarian cancer: how does BRCA or HRD status change who benef

The clinical landscape of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer is defined by two major themes: the biological gradient of homologous recombination deficiency (HRD) and later overall survival (OS) findings that reshaped global approvals.

---

1. How BRCA and HRD Status Shape Who Benefits

PARP inhibitors exploit synthetic lethality: cells unable to repair double-strand DNA breaks via homologous recombination rely heavily on PARP-mediated single-strand repair. When PARP is inhibited, unrepaired damage leads to catastrophic cell death.

Clinical trials across all three agents demonstrate a clear hierarchy of benefit:

---

2. Comparison of the Three Agents

Olaparib (Lynparza)

• First-line maintenance:
  • Monotherapy (SOLO-1): Exclusively for BRCA-mutated patients.
  • Combination with Bevacizumab (PAOLA-1): Approved for HRD-positive tumors (both BRCAm and BRCAwt/HRD+). In PAOLA-1, patients whose tumors were HRP derived no clinical benefit from adding olaparib to bevacizumab.
• Tolerability signature: Anemia, nausea, fatigue, elevated serum creatinine (benign transporter inhibition).

Niraparib (Zejula)

• First-line maintenance (PRIMA):
  • Evaluated as an all-comer maintenance therapy following platinum response in high-risk advanced disease.
  • Benefit was strongly biomarker-driven: median PFS was greatest in the HRD+ cohort, while the HRP subgroup saw a modest PFS extension (~2–3 months).
  • Unique feature: retains an all-comer label in the first-line setting in several jurisdictions, though benefit in HRP is limited.
• Tolerability signature: Thrombocytopenia and hypertension (driven by DAT/NET inhibition), requiring individualized starting doses based on baseline weight and platelet count.

Rucaparib (Rubraca)

• First-line maintenance (ATHENA-MONO):
  • Demonstrated PFS prolongation across all-comers, with the largest effect size in the BRCA-mutated and HRD-positive populations.
• Recurrent maintenance (ARIEL3):
  • Originally tested in all-comers, showing a stepwise drop in benefit from BRCAm $\to$ HRD+ $\to$ BRCAwt/HRP.
• Tolerability signature: Elevated transaminases (ALT/AST, typically transient), elevated serum creatinine, and photosensitivity/rash.

---

3. What Later Overall Survival (OS) Data Revealed

Early approvals for PARP inhibitors were largely based on impressive progression-free survival (PFS) endpoints. However, when mature OS data arrived, they presented two contrasting pictures depending on the setting:

A. First-Line Setting: Strong Confirmation of Long-Term Survival

• SOLO-1 (Olaparib): Seven-year follow-up showed an extraordinary, statistically significant and clinically meaningful OS benefit in BRCA-mutated advanced ovarian cancer (median OS not reached vs. 75.2 months with placebo; HR 0.55). Two-thirds of patients treated with 2 years of maintenance olaparib were alive at 7 years.
• PAOLA-1 (Olaparib + Bevacizumab): Five-year OS data demonstrated a marked survival improvement for the HRD-positive subgroup (HR 0.62 in BRCAm; HR ~0.65 in non-BRCA HRD+). In stark contrast, the HRP subgroup derived zero OS benefit (HR ~1.19), reinforcing that olaparib should not be added to bevacizumab in HR-proficient patients.

B. Recurrent & Heavily Pretreated Settings: Label Contractions and Detriment

In platinum-sensitive recurrent maintenance and late-line treatment, mature OS analyses exposed unexpected risks, triggering broad regulatory restrictions:

1. Complete Withdrawal of Monotherapy Treatment Indications:
   • Trials in heavily pretreated populations (e.g., SOLO3 for olaparib, ARIEL4 for rucaparib, and QUADRA for niraparib) revealed that late-line PARP monotherapy did not improve OS and, in some subgroups, trended toward worse OS compared to standard chemotherapy.
   • Regulators withdrew the treatment indications for patients with prior lines of chemotherapy across all three agents.
2. Restriction of Second-Line+ Maintenance Indications:
   • Niraparib (NOVA): Final OS data showed a potential detrimental trend in the non-germline BRCA cohort. The FDA and EMA consequently restricted its recurrent maintenance label strictly to germline BRCA-mutated disease.
   • Rucaparib (ARIEL3): Similarly, mature OS did not support broad use in biomarker-unselected recurrence, restricting maintenance to patients with deleterious BRCA mutations.

Summary Takeaways

• Biomarker testing (BRCA and HRD) is essential: Patients with BRCA mutations achieve durable, disease-altering OS gains in first-line maintenance.
• HR-proficient disease: Receives marginal, non-durable PFS improvements without demonstrable OS benefit; toxicity and secondary myeloid neoplasm risks must be weighed carefully.
• The setting matters: While PARP inhibition upfront in biomarker-selected patients produces clear survival gains, repeated or late-line use in recurrent, pretreated disease carries diminishing returns and risks of negative survival trends.